PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Immunisation and Countermeasures Division, National Infection Service, Public Health England, London, United Kingdom.\', \'Virus Reference Department, National Infection Service, Public Health England, London, United Kingdom.\', \'Statistics, Modelling and Economics Department, National Infection Service, Public Health England, London, United Kingdom.\', \'Brondesbury Medical Centre, Kilburn, London, United Kingdom.\', \'Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, United Kingdom.\', \'Paediatric Infectious Diseases Research Group, St. George\'s University of London, London, United Kingdom.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.2807/1560-7917.ES.2021.26.12.2100329
?:hasPublicationType
?:journal
  • Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
is ?:pmid of
?:pmid
?:pmid
  • 33769252
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
?:title
  • Robust antibody responses in 70-80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all